Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
[2025]372-001
Phase 3 small_molecule active
Quick answer
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) for Acute Ischemic Stroke is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Acute Ischemic Stroke
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active